Opportunity, I do agree that spending the money to obtain FDA approval would increase the share price. The share price would peak and fall back unless revenue begins.
None of the data from any studies done so far are valid for FDA submission. RPC recently paid a company $330,000 to conduct trials to show their new antigen, the old one is no longer available, is comparable to the previous results from the old test.
The above is NOT an extensive trial as would be needed for the initial approval of RECAF. Opportunity, it WILL BE EXPENSIVE to run the FDA approved clinical trial to even file with the FDA. Thus far, it does not appear that Moro is willing to spend the money and attempt self marketing.
The reality is that if someone was really interested in marketing the ELISA test, they would have already stepped forward and signed a license. Remember, Moro said he was going to license the test to laboratories back in May of 2008. That was 2 1/2 years ago and no one was signed.
News 
Market Data 
Discover 
